Mylan Launches US Advair Rival, Wixela Inhub, At A 70% Discount
Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.
You may also be interested in...
Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.
Hikma has restarted launch activities for its generic version of GSK’s Advair respiratory blockbuster in the US, after the FDA gave the go-ahead following approval of an ANDA amendment.
Lannett has become the latest company to file an ANDA for a generic rival to GSK’s Advair Diskus in the US. Meanwhile, the company has revealed that it is also exploring further respiratory opportunities.